Research into psychedelic therapies is expanding, with compounds such as psilocybin, MDMA, DMT, and LSD currently in clinical trials.
These substances may offer innovative treatment options for psychiatric conditions including PTSD, major and treatment-resistant depression, generalized anxiety, and substance use disorders. Despite recent setbacks, the field continues to gain momentum, driven by key tailwinds such as emerging clinical evidence, regulatory shifts, and growing patient interest.
This CRA Insights explores how psychedelic therapies could open a new era in the treatment of psychiatric disorders and present significant opportunities to improve patient outcomes in a field marked by high unmet need and limited innovative treatment options.
